ESMO 2026 | HIMALAYA: 7-year survival of tremelimumab and durvalumab in HCC

Himalaya is a phase 3 study that tested STRIDE, the combination of a single primary dose of Tremelimumab followed by Durvalumab versus Sorafenib and also included a Durvalumab single agent arm that was tested for non-inferiority versus Sorafenib. The trial is positive and STRIDE is one of the standards of care in first line for patients with advanced HCC. The 7-year overall survival analysis presented here showed that, first, this is the longest follow-up for a combination, for a therapy in first-line treatment for patients with advanced HCC. And we showed that 14% of the patients are alive at seven years. And if we consider patients with disease control, not only objective response, but also stable disease, we have 20% of the patients alive at seven years and if we consider patients with a disease control not only objective response but also stable disease we have 20% of the patients alive at seven years and this is unprecedented results we don’t have anything similar with other treatment options at least so far the safety profile was maintained so there were no new serious adverse events after the five-year survival analysis that was presented a couple of years ago. And also, in terms of baseline liver function, the benefit of STRIDE was maintained regardless of baseline ALBI grade, ALBI grade 1 and ALBI grade 2. So again, this is unprecedented results. We showed that patients can live longer with advanced HCC, and the benefit is maintained regardless of baseline liver function.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.